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In the process of evolving from a normal cell into a malignant cancer, tumors accumulate numerous
genetic aberrations, which should render themhighly visible and susceptible to immune destruction,
yet the unaided immune system fails to eliminate cancer. Decades of research has finally culminated
in an ever-increasing understanding of the mechanisms by which tumors evade and suppress host
immunity.With this understanding has come a renaissance in cancer therapy as immunotherapeutic
interventions, which augment tumor-specific responses and block suppressive pathways on which
tumors depend to maintain their immune privilege, have shown increasing efficacy in the clinic.
The unprecedented therapeutic success of T cell checkpoint blockade and T cell adoptive cell
therapy approaches in solid tumors, such as melanoma, and in certain leukemias led to Cancer
Immunotherapy being named “Breakthrough of the Year” by Science magazine in 2013 (1).
Antibodies, which block the T cell co-inhibitory receptors, CTLA-4 and PD-1, have now achieved
FDA approval for melanoma and lung cancer (PD-1), and numerous other immunotherapeutics are
demonstrating efficacy in clinical trials. These drugs have introduced the hope of curative outcomes
for metastatic cancer patients for whom benefit was previously measured in weeks to months of
extended survival (2). The reality, however, is that <10% of melanoma patients achieve complete
responses to these therapies, fewer than 5% of lung cancer patients do, and for many solid tumors,
such as pancreatic or colorectal cancer, complete responses are almost never observed. This shift in
the goal of immunotherapy from demonstration of therapeutic efficacy toward achieving complete
responses in a majority of patients has highlighted the necessity for combining immunotherapeutics
with similar interventions, as well as with more traditional oncology therapies, in order to achieve
synergistic outcomes.
This special issue on “Advances in Combination Tumor Immunotherapy” highlights both
emerging clinical immunotherapy combinations, promising future combinations centered on T cell
co-stimulatory agonist antibodies based on extensive pre-clinical data, the potential of augmenting
immunotherapy through combination with non-immune-based therapies, and the combinations of
immune and non-immune therapiesmoving forward for tumors of specific histologies (e.g. prostate,
AML). Combination blockade of CTLA-4 and PD-1 in malignant melanoma has yielded objective
response rates over 55% with nearly 90% of patients surviving at 2 years versus a 2-year survival
in this population of <20% as recently as 2010. Callahan and colleagues review the efficacy and
toxicity of this potent combination of checkpoint blockade antibodies in trials of melanoma, renal
cell carcinoma, and non-small cell lung cancer in their article “CTLA-4 and PD-1 pathway blockade:
combinations in the clinic” (3). As this is likely to become the first FDA approved combination
of immunomodulatory antibodies, understanding its clinical application as well as its potential
and limitations when applied across multiple tumor histologies will provide a template for both
assembling and judging the efficacy of future immune combinations.
Antibodies, which activate tumor-specific T cell responses by blocking co-inhibitory check-
point receptors, have rapidly advanced to FDA approval, while those that act by activating
co-stimulatory receptors to increase T cell effector function, proliferation, and survival have moved
more slowly through clinical trials. Promising data from ongoing Phase I trials, coupled with
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potent enhancement of checkpoint antibodies in pre-clinical
studies, predicts a critical role for these agonist antibodies in
future combination therapies. Antibodies, which activate the
tumor-necrosis factor receptor superfamily member (TNFRSF)
OX40 (CD134), drive potent anti-tumor immune responses both
alone and in combination with checkpoint blockade in pre-
clinical models. In their article “OX40 Agonists and Combination
Immunotherapy: Putting the Pedal to the Metal,” Linch et al.
highlight the extensive pre-clinical data on this promising new
class of agents as well as the rationale for combining OX40
antibodies with numerous other therapies (4). Importantly, they
emphasize the very mild safety profile of OX40 agonists, which
make them appealing both in combination studies and in treating
patients with earlier stages of disease. 4-1BB (CD137) is another
TNFRSF member related to OX40 for which agonist antibodies
have been in clinical trials for nearly a decade. Bartkowiak and
colleagues highlight the capacity of 4-1BB agonists, alone or in
a variety of combination strategies, to cure tumors of virtually
every lineage in murine models in their article “4-1BB Agonists:
Multi-Potent Potentiators of Tumor Immunity” (5). The immense
clinical potential of 4-1BB activation has yet to be realized due
to the propensity of these antibodies to cause dose-limiting liver
inflammation; however, recent discoveries may point to a path
forward for these drugs in specific combinations, which enhance
their efficacy while minimizing their side effects.
Traditional therapies, which increase the access of effector lym-
phocytes to the tumor parenchyma and augment the presentation
of tumor-associated antigens, will be invaluable as part of combi-
nations, which promote complete therapeutic responses. Vatner
et al. describe how “Combinations of Immunotherapy and Radia-
tion in Cancer Therapy” work together to diminish immune sup-
pressive stromal populations in the microenvironment, enhance
tumor antigen presentation, and increase access of T cells to
irradiated lesions where they can be primed to seek out other,
non-irradiated lesions, in order to mediate abscopal responses
(6). Similarly, Heninger and colleagues describe how “Aug-
menting Antitumor Immune Responses with Epigenetic Mod-
ifying Agents” can form the backbone of a promising new
approach to combination immunotherapy (7). Targeted modu-
lation of epigenetic mechanisms of gene regulation can render
tumors more immunogenic, stromal populations less suppres-
sive, and increase the potency of immune effectors, yet the tar-
gets of these compounds are broad and care must be taken to
select agents that have a net beneficial effect on tumor immune
elimination.
The first FDA approved tumor vaccine targets prostate cancer,
yet its effects are modest and immunotherapeutic combinations
are sorely needed for castration-resistant disease. Burotto et al.
propose many innovative combinations of immune and tradi-
tional therapies for prostate cancer as well as reviewing the pre-
clinical and clinical experience with these combinations to date in
their article “Exploiting Synergy: Immune-Based Combinations
in the Treatment of Prostate Cancer” (8). Clinical development of
immunotherapies targeting Acute Myeloid Leukemia has lagged
despite promising pre-clinical studies highlighting a diverse array
of vaccine, checkpoint, and innate combinations. Curran et al.
describe the progress to date as well as identifying the combina-
tions with the greatest clinical potential in their article “Targeting
the Innate Immune System as Immunotherapy for Acute Myeloid
Leukemia” (9).
Only through therapeutic combinations will we reach the goal
of delivering curative cancer responses to a majority of patients.
The articles in this issue describe several promising pathways
along the road to achieving this goal.
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